Focused update: Guidelines of care for the management of actinic keratosis

Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guidelin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Dermatology 2022-08, Vol.87 (2), p.373-374.e5
Hauptverfasser: Eisen, Daniel B., Dellavalle, Robert P., Frazer-Green, Lindsy, Schlesinger, Todd E., Shive, Melissa, Wu, Peggy A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 374.e5
container_issue 2
container_start_page 373
container_title Journal of the American Academy of Dermatology
container_volume 87
creator Eisen, Daniel B.
Dellavalle, Robert P.
Frazer-Green, Lindsy
Schlesinger, Todd E.
Shive, Melissa
Wu, Peggy A.
description Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. A multidisciplinary work group conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Two trials were identified, and analysis of the evidence resulted in 1 recommendation. This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AK was made on the basis of the available evidence.
doi_str_mv 10.1016/j.jaad.2022.04.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2652864619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962222006120</els_id><sourcerecordid>2652864619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3153-de62f3c3eb523e4b82072a9bfb72560d0c691cc877c4e9b455ad1a8b69b71a463</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0EgmXhByhQSpqE8SN2jGjQiqeQaKC2HHsCXjbJYidI_D1ZLVBSTXHPvdIcQk4oFBSoPF8WS2t9wYCxAkQBlO-QGQWtcqkqtUtmQDXkWjJ2QA5TWgKAFlztkwNeCq4lqBl5uOndmNBn49rbAS-y2zF4XIUOU9Y3mbMRs6aP2fCGWWs7-4otdsMmsm4IXXDZO0Y79CmkI7LX2FXC4587Jy8318-Lu_zx6fZ-cfWYO05LnnuUrOGOY10yjqKuGChmdd3UipUSPDipqXOVUk6grkVZWk9tVUtdK2qF5HNytt1dx_5jxDSYNiSHq5XtsB-TYbJklRSS6gllW9TFPqWIjVnH0Nr4ZSiYjUOzNBuHZuPQgDCTw6l0-rM_1i36v8qvtAm43AI4ffkZMJrkAnYOfYjoBuP78N_-NzBsgb8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2652864619</pqid></control><display><type>article</type><title>Focused update: Guidelines of care for the management of actinic keratosis</title><source>Elsevier ScienceDirect Journals</source><creator>Eisen, Daniel B. ; Dellavalle, Robert P. ; Frazer-Green, Lindsy ; Schlesinger, Todd E. ; Shive, Melissa ; Wu, Peggy A.</creator><creatorcontrib>Eisen, Daniel B. ; Dellavalle, Robert P. ; Frazer-Green, Lindsy ; Schlesinger, Todd E. ; Shive, Melissa ; Wu, Peggy A.</creatorcontrib><description>Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. A multidisciplinary work group conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Two trials were identified, and analysis of the evidence resulted in 1 recommendation. This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AK was made on the basis of the available evidence.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2022.04.013</identifier><identifier>PMID: 35439607</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>actinic keratosis ; actinic keratosis guidelines ; clinical guidelines for actinic keratosis ; tirbanibulin ; topical agents</subject><ispartof>Journal of the American Academy of Dermatology, 2022-08, Vol.87 (2), p.373-374.e5</ispartof><rights>2022 American Academy of Dermatology, Inc.</rights><rights>Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3153-de62f3c3eb523e4b82072a9bfb72560d0c691cc877c4e9b455ad1a8b69b71a463</citedby><cites>FETCH-LOGICAL-c3153-de62f3c3eb523e4b82072a9bfb72560d0c691cc877c4e9b455ad1a8b69b71a463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaad.2022.04.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35439607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eisen, Daniel B.</creatorcontrib><creatorcontrib>Dellavalle, Robert P.</creatorcontrib><creatorcontrib>Frazer-Green, Lindsy</creatorcontrib><creatorcontrib>Schlesinger, Todd E.</creatorcontrib><creatorcontrib>Shive, Melissa</creatorcontrib><creatorcontrib>Wu, Peggy A.</creatorcontrib><title>Focused update: Guidelines of care for the management of actinic keratosis</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. A multidisciplinary work group conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Two trials were identified, and analysis of the evidence resulted in 1 recommendation. This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AK was made on the basis of the available evidence.</description><subject>actinic keratosis</subject><subject>actinic keratosis guidelines</subject><subject>clinical guidelines for actinic keratosis</subject><subject>tirbanibulin</subject><subject>topical agents</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOxDAQRS0EgmXhByhQSpqE8SN2jGjQiqeQaKC2HHsCXjbJYidI_D1ZLVBSTXHPvdIcQk4oFBSoPF8WS2t9wYCxAkQBlO-QGQWtcqkqtUtmQDXkWjJ2QA5TWgKAFlztkwNeCq4lqBl5uOndmNBn49rbAS-y2zF4XIUOU9Y3mbMRs6aP2fCGWWs7-4otdsMmsm4IXXDZO0Y79CmkI7LX2FXC4587Jy8318-Lu_zx6fZ-cfWYO05LnnuUrOGOY10yjqKuGChmdd3UipUSPDipqXOVUk6grkVZWk9tVUtdK2qF5HNytt1dx_5jxDSYNiSHq5XtsB-TYbJklRSS6gllW9TFPqWIjVnH0Nr4ZSiYjUOzNBuHZuPQgDCTw6l0-rM_1i36v8qvtAm43AI4ffkZMJrkAnYOfYjoBuP78N_-NzBsgb8</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Eisen, Daniel B.</creator><creator>Dellavalle, Robert P.</creator><creator>Frazer-Green, Lindsy</creator><creator>Schlesinger, Todd E.</creator><creator>Shive, Melissa</creator><creator>Wu, Peggy A.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220801</creationdate><title>Focused update: Guidelines of care for the management of actinic keratosis</title><author>Eisen, Daniel B. ; Dellavalle, Robert P. ; Frazer-Green, Lindsy ; Schlesinger, Todd E. ; Shive, Melissa ; Wu, Peggy A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3153-de62f3c3eb523e4b82072a9bfb72560d0c691cc877c4e9b455ad1a8b69b71a463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>actinic keratosis</topic><topic>actinic keratosis guidelines</topic><topic>clinical guidelines for actinic keratosis</topic><topic>tirbanibulin</topic><topic>topical agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eisen, Daniel B.</creatorcontrib><creatorcontrib>Dellavalle, Robert P.</creatorcontrib><creatorcontrib>Frazer-Green, Lindsy</creatorcontrib><creatorcontrib>Schlesinger, Todd E.</creatorcontrib><creatorcontrib>Shive, Melissa</creatorcontrib><creatorcontrib>Wu, Peggy A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eisen, Daniel B.</au><au>Dellavalle, Robert P.</au><au>Frazer-Green, Lindsy</au><au>Schlesinger, Todd E.</au><au>Shive, Melissa</au><au>Wu, Peggy A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Focused update: Guidelines of care for the management of actinic keratosis</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>87</volume><issue>2</issue><spage>373</spage><epage>374.e5</epage><pages>373-374.e5</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. A multidisciplinary work group conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Two trials were identified, and analysis of the evidence resulted in 1 recommendation. This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AK was made on the basis of the available evidence.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35439607</pmid><doi>10.1016/j.jaad.2022.04.013</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0190-9622
ispartof Journal of the American Academy of Dermatology, 2022-08, Vol.87 (2), p.373-374.e5
issn 0190-9622
1097-6787
language eng
recordid cdi_proquest_miscellaneous_2652864619
source Elsevier ScienceDirect Journals
subjects actinic keratosis
actinic keratosis guidelines
clinical guidelines for actinic keratosis
tirbanibulin
topical agents
title Focused update: Guidelines of care for the management of actinic keratosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A51%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Focused%20update:%20Guidelines%20of%20care%20for%20the%20management%20of%20actinic%20keratosis&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Eisen,%20Daniel%20B.&rft.date=2022-08-01&rft.volume=87&rft.issue=2&rft.spage=373&rft.epage=374.e5&rft.pages=373-374.e5&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2022.04.013&rft_dat=%3Cproquest_cross%3E2652864619%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2652864619&rft_id=info:pmid/35439607&rft_els_id=S0190962222006120&rfr_iscdi=true